Physician profile
John H Lacy
NPI 1053461715
$653.36
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $112 · 2021: $215 · 2022: $60.37 · 2023: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $157.12 | 2021 | |
| Portola Pharmaceuticals, LLC | $86.27 | 2019-2020 | |
| Smith+Nephew, INC. | $62.32 | 2021-2023 | Iodosorb Ointment 40g USA, Collagenase Santyl, Grafix |
| Organogenesis INC. | $47.70 | 2021-2023 | Puraply |
| Davol INC. | $47.53 | 2020 | |
| Kci USA, INC. | $45.44 | 2023 | Snap, Promogran Prisma, Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $28.00 | 2022-2023 | Nuzyra |
| Covidien LP | $26.02 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.99 | 2020 | |
| Myriad Genetic Laboratories, INC. | $24.31 | 2021 | |
| Medline Industries LP | $17.73 | 2023 | |
| Melinta Therapeutics, LLC | $15.62 | 2022 | |
| Medtronic USA, INC. | $15.53 | 2019 | |
| Merck Sharp & Dohme LLC | $15.24 | 2019 | |
| Aroa Biosurgery Incorporated | $15.07 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $12.24 | 2022 | |
| Novo Nordisk INC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lacy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.